Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment

BACKGROUND: Both statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors lower blood low-density lipoprotein cholesterol levels to reduce risk of cardiovascular events. To assess potential differences between metabolic effects of these 2 lipid-lowering therapies, we performed de...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation
Hauptverfasser: Sliz, Eeva, Kettunen, Johannes, Holmes, Michael V., Williams, Clare Oliver, Boachie, Charles, Wang, Qin, Männikkö, Minna, Sebert, Sylvain, Walters, Robin, Lin, Kuang, Millwood, Iona Y., Clarke, Robert, Li, Liming, Rankin, Naomi, Welsh, Paul, Delles, Christian, Jukema, J. Wouter, Trompet, Stella, Ford, Ian, Perola, Markus, Salomaa, Veikko, Järvelin, Marjo-Riitta, Chen, Zhengming, Lawlor, Debbie A., Ala-Korpela, Mika, Danesh, John, Davey Smith, George, Sattar, Naveed, Butterworth, Adam, Würtz, Peter
Format: Artigo
Sprache:Inglês
Veröffentlicht: Lippincott Williams & Wilkins 2018
Schlagworte:
Original Research Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6254781/
https://ncbi.nlm.nih.gov/pubmed/30524137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.118.034942
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge